The FDA has approved a new subcutaneous induction regimen for SKYRIZI (risankizumab-rzaa) to treat adults with moderately to severely active Crohn's disease. This allows patients to start treatment at home using an on-body injector (OBI) device, improving convenience and flexibility. The approval follows positive Phase 3 AFFIRM trial results showing superior clinical remission and endoscopic response at week 12, especially in patients without prior advanced therapy failure. The safety profile remains consistent with no new risks identified, and updated prescribing information now allows healthcare providers to use clinical judgment regarding tuberculosis testing before treatment.
AbbVie Inc (ABBV) trades at USD 285.83 on Pluang as of Oct 24, 2026 02:51 WIB, up 0.33% in the last day. The stock is near its 52-week high of USD 289.00, with a market cap of $503.96 billion. Despite the positive FDA news, Pluang order activity shows 72% sell and 28% buy, reflecting mixed investor sentiment.
Johnson & Johnson reported strong pharmaceutical growth with Innovative Medicine up 7.9%, driving optimism for its stock with a 12-month price target of $288.66, an 11.48% upside. However, its MedTech segment showed weak international sales growth an...
AbbVie announced positive Phase 3 INTREPID study results for lutikizumab, a dual IL-1α/1β antagonist, in treating moderate to severe hidradenitis suppurativa (HS). The study met its primary endpoint with 31.4% of patients achieving HiSCR75 at Week 16...
Retirees are increasingly turning to high-yield dividend stocks from diverse industries to supplement income beyond Social Security's fixed cost-of-living adjustments. Stocks like Verizon, Altria, AbbVie, Realty Income, and Enbridge offer yields from...
AbbVie has partnered with McLaren Racing as an Official Pharmaceutical Partner, launching the Race to Innovate campaign at the 2026 U.S. Grand Prix. For every 10 Constructors' Championship points McLaren earns, AbbVie will donate $10,000 to global ch...
In a Phase 2a study, ABBV-466, a dual-targeting therapy by AbbVie, achieved significantly higher endoscopic remission rates in Crohn's disease patients at Week 12 compared to anti-IL-23 p19 or anti-α4β7 monotherapies. The remission advantage increase...
